2026 Regular Session
HB484
Corporate Income Tax - Addition Modification - Direct-to-Consumer Pharmaceutical Advertising
Providing an addition modification under the corporate income tax for the amount of certain direct-to-consumer advertising expenses for certain covered drugs paid or incurred during the taxable year that are deducted under the Internal Revenue Code; and applying the Act to all taxable years beginning after December 31, 2025.
Legislative progress
i
This summary includes only completed milestones supported by recorded actions. It does not predict the next step, and it preserves later committee reassignments, concurrence, conference, veto, and approval actions when they occur.
Committee referrals
January 23, 2026 · House
Ways and Means
Instrument history
i
This is the complete recorded action history in the current source package. Highlighted entries are marked as significant by the source. A roll-call link appears only when a vote-like action has one unambiguous same-day chamber vote.
-
House Hearing 2/12 at 1:00 p.m.
-
House First Reading Ways and Means